Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3844583 in Healthy Participants, and Multiple-Dose Study of LY3844583 in Healthy Participants and Patients With Atopic Dermatitis

NCT05486208 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05486208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05486208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3844583 in Healthy Participants, and Multiple-Dose Study of LY3844583 in Healthy Participants and Patients With Atopic Dermatitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
August 11, 2022
Completion date
January 20, 2024
Enrollment
86 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic, healthy